This matches what the scientists expected given that LIG1 K845N slows symptoms of HD in people. It also suggests that the special way that LIG1 K845N checks over and seals up DNA tiles also somehow ...
In 2025, HDBuzz published 100 articles, double our output from the year before and more than triple our historical average.
In plain language. Written by scientists. For the global HD community.
SKY-0515 is a daily oral drug designed to lower both huntingtin, the protein that drives HD, and PMS1, a DNA repair protein linked to somatic CAG repeat expansion. Researchers hope this dual-target ...
In plain language. Written by scientists. Wave Life Sciences shared the disappointing news that their two ASOs in Phase 1/2 trials in HD patients did not successfully lower mutant huntingtin. Many HD ...
In plain language. Written by scientists. Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntington’s disease observational trials to model ...
When it comes to clearing up the mess created by mutant Huntingtin (HTT) we tend to think of sending external help into the brain, in the form of HTT lowering drugs or anti-sense oligonucleotides ...
Regular HDBuzz readers may recall our September 2024 article examining the long history of pridopidine in Huntington’s disease (HD) research. In that piece, we covered the drug’s journey through four ...
In plain language. Written by scientists. ⏱️ 5 min read | Prilenia’s application for European approval of pridopidine was quietly withdrawn 6 months ago, in November 2025, after the EMA had already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results